{"abstract_id": 3392, "endpoint_id": 168, "truth": 1, "pred": 1, "blended_prob": 0.867448275862069, "llm_prob": 0.94, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Small sample size (n=24) and single\u2011arm design may limit robustness"], "green": []}, "rationale": "The phase\u202fII single\u2011arm trial reported an overall response rate of 75%, which exceeds the pre\u2011specified 60% threshold for further study; the endpoint is clearly defined and met despite the modest cohort size.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 2892, "endpoint_id": 125, "truth": 1, "pred": 1, "blended_prob": 0.6200000000000001, "llm_prob": 0.45, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient safety data in retrieved evidence to confirm absence of new safety signals"], "green": []}, "rationale": "The trial abstract states no new safety signals, but the retrieved evidence does not contain any safety outcome data or analysis. Without cited safety results, the decision rule cannot be confidently affirmed.", "citations": []}
{"abstract_id": 1698, "endpoint_id": 100, "truth": 1, "pred": 1, "blended_prob": 0.879448275862069, "llm_prob": 0.96, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial reports an objective response rate by independent central review of 20.0% in Group B with a one\u2011sided p\u2011value of 0.0362, which is below the 0.05 threshold set for the primary hypothesis, indicating the primary endpoint is met despite the modest sample size (n=15).", "citations": [{"title": "Tasurgratinib phase 2 basket trial (NCT04962867) \u2013 primary endpoint results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04962867"}]}
{"abstract_id": 4719, "endpoint_id": 247, "truth": 1, "pred": 1, "blended_prob": 0.5700000000000001, "llm_prob": 0.55, "base_prob": 0.6, "base_note": "Base rate from unknown / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for biomarker exploration outcome is not directly cited from retrieved sources; reliance on trial description reduces confidence."], "green": []}, "rationale": "The phase II randomized trial reports that immunological biomarkers (Th7R and Th2) significantly correlated with progression\u2011free and overall survival for osimertinib, fulfilling the exploratory biomarker co\u2011primary endpoint, although no biomarkers affected afatinib outcomes.", "citations": []}
{"abstract_id": 3679, "endpoint_id": 190, "truth": 1, "pred": 1, "blended_prob": 0.61, "llm_prob": 0.55, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient citation for irAE data"], "green": []}, "rationale": "The study reports immune-related adverse events in 5 (6.7%) patients receiving toripalimab and none in the control arm, with a p\u2011value of 0.058, which meets the decision rule of no significant difference (p\u202f\u2265\u202f0.05).", "citations": []}
{"abstract_id": 1825, "endpoint_id": 271, "truth": 1, "pred": 1, "blended_prob": 0.725, "llm_prob": 0.75, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target wee1 kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Sample size not reported, limiting robustness of exposure assessment"], "green": []}, "rationale": "The trial report explicitly states that no major changes were observed in etoposide exposure across Debio 0123 dose levels and that exposure was consistent with historical data, directly supporting the decision rule of absence of major changes.", "citations": [{"title": "Debio 0123-SCLC-104 trial abstract (e15127)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05815160"}]}
{"abstract_id": 1288, "endpoint_id": 76, "truth": 1, "pred": 1, "blended_prob": 0.7095, "llm_prob": 0.62, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target ep4 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for safety outcome is only from trial description, not present in retrieved external sources; citation support is indirect."], "green": []}, "rationale": "The trial reports that no treatment\u2011related serious or grade\u202f>\u202f3 adverse events occurred among the 27 patients, directly satisfying the primary safety decision rule, though external citations do not corroborate this specific finding.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 6202, "endpoint_id": 48, "truth": 1, "pred": 1, "blended_prob": 0.8600000000000001, "llm_prob": 0.85, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target thrombopoietin receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the statistical significance of the time\u2011to\u2011first platelet response is limited to the trial abstract; no independent source was retrieved."], "green": []}, "rationale": "The phase\u20113 RCT randomized 165 patients (2:1) to romiplostim vs placebo and reported a median time to first platelet response of 1.1 weeks vs 2.1 weeks with P\u202f<\u202f0.001, satisfying the superiority decision rule (p\u2011value < alpha). Sample size and randomization are adequate for this endpoint.", "citations": [{"title": "Romiplostim versus placebo for chemotherapy\u2011induced thrombocytopenia in gastrointestinal cancers (NCT03362177)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT03362177"}]}
{"abstract_id": 2329, "endpoint_id": 122, "truth": 0, "pred": 1, "blended_prob": 0.8461176470588236, "llm_prob": 0.92, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["small sample size and exploratory single\u2011arm design limit statistical power"], "green": []}, "rationale": "The exploratory analysis reported log\u2011rank P\u2011values for PFS (P\u202f=\u202f0.519) that are far above the pre\u2011specified significance threshold of 0.05, indicating no statistically significant difference in PFS between DDR\u2011mutated and non\u2011mutated patients. The trial\u2019s single\u2011arm design and only 16 evaluable patients (7 with DDR mutations) further reduce the reliability of any observed trend.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 3719, "endpoint_id": 287, "truth": 1, "pred": 1, "blended_prob": 0.545, "llm_prob": 0.45, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the reported p\u2011value is not present in the retrieved snippets; confidence is limited."], "green": []}, "rationale": "The trial randomized 50 tracheostomized H&N SCC patients and reported a p\u2011value of 0.045 for emotional\u2011well\u2011being improvement, which meets the <0.05 significance criterion; however, the specific result is not corroborated by the retrieved evidence, lowering certainty.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 4390, "endpoint_id": 230, "truth": 1, "pred": 1, "blended_prob": 0.633448275862069, "llm_prob": 0.55, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target alk has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm the reported MPR rate and its statistical significance."], "green": []}, "rationale": "The trial reports a 46% major pathological response, exceeding the Simon's design thresholds for P0=20% and P1=40%, and explicitly states that the primary endpoint was met; however, the retrieved evidence does not contain the specific outcome data, reducing confidence.", "citations": []}
{"abstract_id": 2345, "endpoint_id": 124, "truth": 1, "pred": 1, "blended_prob": 0.723448275862069, "llm_prob": 0.7, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Primary endpoint outcome not directly supported by retrieved evidence; reliance on trial summary details."], "green": []}, "rationale": "The single\u2011arm phase\u202fII study enrolled 37 patients and reported a confirmed ORR of 67.6%, exceeding the pre\u2011specified target of 68% (23 responses) under Simon's minimax design, indicating the primary endpoint was met. The sample size and design are appropriate for a phase\u202fII efficacy assessment, and the ORR definition aligns with standard oncology endpoints.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 1618, "endpoint_id": 96, "truth": 1, "pred": 1, "blended_prob": 0.7857777777777778, "llm_prob": 0.68, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target braf has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["small sample size (n=17) and no DLT observed may limit certainty of MTD determination"], "green": ["biomarker tier GREEN (BRAF target)"]}, "rationale": "The study used a standard 3+3 dose-escalation design with DLT assessment in Cycle\u202f1 and reported no dose\u2011limiting toxicities across five dose levels up to 3600\u202fmg/day, allowing the highest tested dose to be considered the maximum tolerated dose and supporting a recommended Phase\u202f2 dose, despite the modest sample size.", "citations": [{"title": "NCT06536400 \u2013 Phase\u202f1 study of HSK42360 in BRAF V600\u2011mutated solid tumors", "url": "http://www.clinicaltrials.gov/ct2/show/NCT06536400"}]}
{"abstract_id": 6278, "endpoint_id": 49, "truth": 1, "pred": 1, "blended_prob": 0.6005714285714285, "llm_prob": 0.62, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for dyspnea outcome relies solely on trial summary; no independent source retrieved"], "green": []}, "rationale": "The trial reports a dyspnea p\u2011value of 0.02, meeting the pre\u2011specified superiority threshold (p\u202f<\u202f0.05) for this secondary endpoint, but the small sample size (n=40) and lack of external corroboration temper confidence.", "citations": []}
{"abstract_id": 1292, "endpoint_id": 71, "truth": 1, "pred": 1, "blended_prob": 0.718, "llm_prob": 0.7, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["insufficient citation for DLT outcome"], "green": []}, "rationale": "The trial reports that no dose\u2011limiting toxicities were observed across all dose levels, satisfying the primary endpoint decision rule of absence of DLTs. However, the specific statement is not present in the retrieved evidence snippets, reducing confidence.", "citations": []}
